Tags

Type your tag names separated by a space and hit enter

Hyperhomocyst(e)inemia in chronic stable renal transplant patients.
Rev Hosp Clin Fac Med Sao Paulo 2000 Sep-Oct; 55(5):161-8RH

Abstract

PURPOSE

Hyperhomocyst(e)inaemia is an important risk factor for atherosclerosis, which is currently a major cause of death in renal transplant patients. The aim of this study was to assess the influence of immunosuppressive therapy on homocyst(e)inemia in renal transplant recipients.

METHODS

Total serum homocysteine (by high performance liquid chromatography), creatinine, lipid profile, folic acid (by radioimmunoassay-RIA) and vitamin B12 (by RIA) concentrations were measured in 3 groups. Group I patients (n=20) were under treatment with cyclosporine, azathioprine, and prednisone; group II (n=9) were under treatment with azathioprine and prednisone; and group III (n=7) were composed of renal graft donors for groups I and II. Creatinine, estimated creatinine clearance, cyclosporine trough level, lipid profile, folic acid, and vitamin B12 concentrations and clinical characteristics of patients were assessed with the aim of ascertaining determinants of hyperhomocyst(e)inemia.

RESULTS

Patient ages were 48.8 +/- 15.1 yr (group I), 43.3 +/- 11.3 yr (group II); and 46.5 +/- 14.8 yr (group III). Mean serum homocyst(e)ine (tHcy) concentrations were 18.07 +/- 8.29 mmol/l in renal transplant recipients; 16.55 +/- 5.6 mmol/l and 21.44 +/- 12.1 mmol/l respectively for group I (with cyclosporine) and group II (without cyclosporine) (NS). In renal donors, tHcy was significantly lower (9.07 +/- 3.06 mmol/l; group I + group II vs. group III, p<0.008). There was an unadjusted correlation (p<0.10) between age (r=0.427; p<0.005) body weight (r=0.412; p<0.05), serum creatinine (r=0.427; p<0.05), estimated creatinine clearance (r=0.316; p<0.10), and tHcy in renal recipients (group I +II). Independent regressors (r2=0.46) identified in the multiple regression model were age (coefficient= 0.253; p=0.009) and serum creatinine (coefficient=8.07; p=0.045). We found no cases of hyperhomocyst(e)inemia in the control group. In contrast, 38% of renal recipients had hyperhomocyst(e)inemia: 7 cases (35%) on cyclosporine and 4 (45%) without cyclosporine, based on serum normal levels.

CONCLUSIONS

Renal transplant recipients frequently have hyperhomocyst(e)inemia. Hyperhomocyst(e)inemia in renal transplant patients is independent of the scheme of immunosuppression they are taking. The older the patients are and the higher are their serum creatinine levels, the more susceptible they are to hyperhomocyst(e)inemia following renal transplantation.

Authors+Show Affiliations

Division of Urology, Hospital das Clínicas, Faculty of Medicine, University of São Paulo.No affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article

Language

eng

PubMed ID

11175576

Citation

Machado, D J., et al. "Hyperhomocyst(e)inemia in Chronic Stable Renal Transplant Patients." Revista Do Hospital Das Clinicas, vol. 55, no. 5, 2000, pp. 161-8.
Machado DJ, Paula FJ, Sabbaga E, et al. Hyperhomocyst(e)inemia in chronic stable renal transplant patients. Rev Hosp Clin Fac Med Sao Paulo. 2000;55(5):161-8.
Machado, D. J., Paula, F. J., Sabbaga, E., & Ianhez, L. E. (2000). Hyperhomocyst(e)inemia in chronic stable renal transplant patients. Revista Do Hospital Das Clinicas, 55(5), pp. 161-8.
Machado DJ, et al. Hyperhomocyst(e)inemia in Chronic Stable Renal Transplant Patients. Rev Hosp Clin Fac Med Sao Paulo. 2000;55(5):161-8. PubMed PMID: 11175576.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Hyperhomocyst(e)inemia in chronic stable renal transplant patients. AU - Machado,D J, AU - Paula,F J, AU - Sabbaga,E, AU - Ianhez,L E, PY - 2001/2/15/pubmed PY - 2001/5/22/medline PY - 2001/2/15/entrez SP - 161 EP - 8 JF - Revista do Hospital das Clinicas JO - Rev Hosp Clin Fac Med Sao Paulo VL - 55 IS - 5 N2 - PURPOSE: Hyperhomocyst(e)inaemia is an important risk factor for atherosclerosis, which is currently a major cause of death in renal transplant patients. The aim of this study was to assess the influence of immunosuppressive therapy on homocyst(e)inemia in renal transplant recipients. METHODS: Total serum homocysteine (by high performance liquid chromatography), creatinine, lipid profile, folic acid (by radioimmunoassay-RIA) and vitamin B12 (by RIA) concentrations were measured in 3 groups. Group I patients (n=20) were under treatment with cyclosporine, azathioprine, and prednisone; group II (n=9) were under treatment with azathioprine and prednisone; and group III (n=7) were composed of renal graft donors for groups I and II. Creatinine, estimated creatinine clearance, cyclosporine trough level, lipid profile, folic acid, and vitamin B12 concentrations and clinical characteristics of patients were assessed with the aim of ascertaining determinants of hyperhomocyst(e)inemia. RESULTS: Patient ages were 48.8 +/- 15.1 yr (group I), 43.3 +/- 11.3 yr (group II); and 46.5 +/- 14.8 yr (group III). Mean serum homocyst(e)ine (tHcy) concentrations were 18.07 +/- 8.29 mmol/l in renal transplant recipients; 16.55 +/- 5.6 mmol/l and 21.44 +/- 12.1 mmol/l respectively for group I (with cyclosporine) and group II (without cyclosporine) (NS). In renal donors, tHcy was significantly lower (9.07 +/- 3.06 mmol/l; group I + group II vs. group III, p<0.008). There was an unadjusted correlation (p<0.10) between age (r=0.427; p<0.005) body weight (r=0.412; p<0.05), serum creatinine (r=0.427; p<0.05), estimated creatinine clearance (r=0.316; p<0.10), and tHcy in renal recipients (group I +II). Independent regressors (r2=0.46) identified in the multiple regression model were age (coefficient= 0.253; p=0.009) and serum creatinine (coefficient=8.07; p=0.045). We found no cases of hyperhomocyst(e)inemia in the control group. In contrast, 38% of renal recipients had hyperhomocyst(e)inemia: 7 cases (35%) on cyclosporine and 4 (45%) without cyclosporine, based on serum normal levels. CONCLUSIONS: Renal transplant recipients frequently have hyperhomocyst(e)inemia. Hyperhomocyst(e)inemia in renal transplant patients is independent of the scheme of immunosuppression they are taking. The older the patients are and the higher are their serum creatinine levels, the more susceptible they are to hyperhomocyst(e)inemia following renal transplantation. SN - 0041-8781 UR - https://www.unboundmedicine.com/medline/citation/11175576/Hyperhomocyst_e_inemia_in_chronic_stable_renal_transplant_patients_ L2 - https://medlineplus.gov/kidneytransplantation.html DB - PRIME DP - Unbound Medicine ER -